

## **Gilead Sciences Announces 43 Cents Quarterly Dividend Program and \$15 Billion Share Buyback Program**

February 3, 2015 4:07 PM ET

FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 3, 2015-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the company's Board of Directors has authorized a dividend program under which the company intends to pay quarterly dividends of \$0.43 per share, beginning in the second quarter of 2015, subject to quarterly declarations by the Board of Directors.

The Board of Directors also approved the repurchase of up to an additional \$15.0 billion of the company's common stock. This new program is in addition to the currently authorized three-year \$5.0 billion repurchase program (authorized in May 2014). As of December 31, 2014, approximately \$3 billion remained in the May 2014 program. The new program will expire 5 years after the completion of the May 2014 program. Purchases may be made in the open market or in privately negotiated transactions from time to time, as determined by Gilead's management and in accordance with the requirements of the Securities and Exchange Commission.

"The past year was marked by the launch of our first oncology product, second HCV medication, regulatory filings for the next generation HIV medicine, E/C/F/TAF, and a doubling of product revenues relative to 2013. We are entering 2015 with financial strength, a portfolio of 19 marketed products that are addressing significant unmet medical needs and a pipeline for which we expect a number of milestones and data readouts during the coming year," said John Martin. "Today's announcement reflects the Board of Director's and senior management's confidence in Gilead's future."

### **About Gilead**

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

### **Forward-Looking Statement**

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that Gilead may be unable to complete the share repurchase program due to changes in its stock price, corporate or other market conditions. In addition, Gilead may be unable to pay dividends or its Board of Directors may reduce the amount of the dividend for a number of reasons, including, without limitation, due to changes in its financial condition, material developments in Gilead's business or the involvement of Gilead in significant acquisitions. Further, our marketing application for E/C/F/TAF may not be approved by regulatory authorities, and any approvals may have significant limitations on its use. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

*For more information on Gilead Sciences, please visit the company's website at [www.Gilead.com](http://www.Gilead.com), follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.*

Source: Gilead Sciences, Inc.

Gilead Sciences, Inc.

**Investors**

Robin Washington, 650-522-5688

Patrick O'Brien, 650-522-1936

**Media**

Amy Flood, 650-522-5643